- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04296604
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
March 20, 2024 updated by: Joan A Camprodon, MD MPH PhD, Massachusetts General Hospital
In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.
The investigators will select 8 relevant diagnostic categories: traumatic brain injury, major depressive disorder, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, borderline personality disorder and substance use disorder.
The study will also include a cohort of healthy controls for comparison.
Study Type
Interventional
Enrollment (Estimated)
600
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Joan Camprodon, MD, PhD, MPH
- Phone Number: 6177265348
Study Contact Backup
- Name: Patricia Cirillo, MD, PhD
- Phone Number: 6177243217
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02129
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Blake Andreou, BS
- Phone Number: 617-724-8780
- Email: bandreou@mgh.harvard.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria
- Male and female outpatients 18-65 years of age
- A diagnosis of traumatic brain injury, major depressive disorder, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, borderline personality disorder and substance use disorders meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
Exclusion Criteria
- Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, shunts, pacemakers, pregnancy.
- Active substance dependence (except for tobacco and cannabis).
- Pregnant or nursing females.
- Inability to participate in testing procedures.
Additional exclusion criteria for healthy controls:
- Diagnosis of psychiatric of neurological disorder
- Ongoing treatment with any psychotropic medications.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Traumatic Brain Injury
This group consists of individuals diagnosed with traumatic brain injury.
This group will undergo three sessions of tDCS: two active sessions and one sham session.
The order of the sessions is randomized.
|
In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Other Names:
|
Experimental: Major Depressive Disorder
This group consists of individuals diagnosed with major depressive disorder.
This group will undergo three sessions of tDCS: two active sessions and one sham session.
The order of the sessions is randomized.
|
In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Other Names:
|
Experimental: Bipolar Disorder
This group consists of individuals diagnosed with bipolar disorder.
This group will undergo three sessions of tDCS: two active sessions and one sham session.
The order of the sessions is randomized.
|
In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Other Names:
|
Experimental: Schizophrenia
This group consists of individuals diagnosed with schizophrenia.
This group will undergo three sessions of tDCS: two active sessions and one sham session.
The order of the sessions is randomized.
|
In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Other Names:
|
Experimental: Attention Deficit Hyperactivity Disorder
This group consists of individuals diagnosed with attention deficit hyperactivity disorder.
This group will undergo three sessions of tDCS: two active sessions and one sham session.
The order of the sessions is randomized.
|
In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Other Names:
|
Experimental: Borderline Personality Disorder
This group consists of individuals diagnosed with borderline personality disorder.
This group will undergo three sessions of tDCS: two active sessions and one sham session.
The order of the sessions is randomized.
|
In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Other Names:
|
Experimental: Substance Use Disorder
This group consists of individuals diagnosed with substance use disorder.
This group will undergo three sessions of tDCS: two active sessions and one sham session.
The order of the sessions is randomized.
|
In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Other Names:
|
Active Comparator: Healthy Controls
This group consists of individuals diagnosed with healthy controls.
This group will undergo three sessions of tDCS: two active sessions and one sham session.
The order of the sessions is randomized.
|
In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in N-Back Task
Time Frame: Baseline to Post-Treatment, 1 Week
|
Working Memory Task
|
Baseline to Post-Treatment, 1 Week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Flanker Task
Time Frame: Baseline to Post-Treatment, 1 Week
|
Attention and Inhibitory Control Task
|
Baseline to Post-Treatment, 1 Week
|
Change in Multi-Source Interference with International Affective Picture System Task
Time Frame: Baseline to Post-Treatment, 1 Week
|
Cognitive Control During Emotional Regulation Task
|
Baseline to Post-Treatment, 1 Week
|
Change in Delayed Discounting Task
Time Frame: Baseline to Post-Treatment, 1 Week
|
Decision-Making Task
|
Baseline to Post-Treatment, 1 Week
|
Change in Stop Signal Task
Time Frame: Baseline to Post-Treatment, 1 Week
|
Ability to Inhibit a Response Task
|
Baseline to Post-Treatment, 1 Week
|
Change in Iowa Gambling Task
Time Frame: Baseline to Post-Treatment, 1 Week
|
Risk-Taking Task
|
Baseline to Post-Treatment, 1 Week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joan Camprodon, MD, PhD, MPH, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2014
Primary Completion (Estimated)
September 1, 2024
Study Completion (Estimated)
September 1, 2024
Study Registration Dates
First Submitted
February 28, 2020
First Submitted That Met QC Criteria
March 4, 2020
First Posted (Actual)
March 5, 2020
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mood Disorders
- Wounds and Injuries
- Schizophrenia Spectrum and Other Psychotic Disorders
- Craniocerebral Trauma
- Trauma, Nervous System
- Bipolar and Related Disorders
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Substance-Related Disorders
- Personality Disorders
- Depressive Disorder
- Schizophrenia
- Brain Injuries
- Brain Injuries, Traumatic
- Bipolar Disorder
- Attention Deficit Disorder with Hyperactivity
- Depressive Disorder, Major
- Borderline Personality Disorder
Other Study ID Numbers
- 2014P001428
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Transcranial Direct Current Stimulation
-
Federal University of ParaíbaCompleted
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
University of Campinas, BrazilUnknownEpilepsy IntractableBrazil
-
Dina Hatem ElhammadyUnknown
-
Shirley Ryan AbilityLabNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedStroke | Nonfluent AphasiaUnited States
-
University of Texas Rio Grande ValleyRecruitingSpinal Cord Diseases | Spinal Cord InjuriesUnited States
-
Federal University of ParaíbaUnknown
-
University of CalgaryAlberta Health servicesRecruitingCervicogenic HeadacheCanada
-
Universidade Federal do Rio Grande do NorteNot yet recruitingLow Back Pain | Transcranial Direct Current Stimulation
-
Nanyang Technological UniversityActive, not recruiting